DHR
NYSE · Life Sciences Tools & Services
Danaher Corp
$202.45
-1.44 (-0.71%)
DHR News16 articles
Avantor Surges 15% on Sales Beat, but Margin Concerns Persist
Avantor (AVTR) shares surged 15% after Q2 results beat estimates, but margin and cash-flow targets remained unchanged, signaling a demand reset.
Danaher's 50% Rebound Faces $100M Bioprocessing Deferral Hurdle
Danaher shares rebounded 50% from a post-earnings drop, but a $100 million bioprocessing revenue delay to 2027 tests the recovery.
Thermo Fisher Stock Surges on Strong Instrument Profit Growth
Thermo Fisher shares rose roughly 10% after Q2 revenue beat estimates and the company boosted its profit outlook, driven by strong margin expansion in Analytical Instruments.
Danaher Plunges 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares dropped 11% after its biotech segment underperformed expectations, leading to a valuation adjustment. Full-year core growth guidance was narrowed to 3%-4%.
Danaher Tumbles 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares plunged 11% on Tuesday after biotech growth fell short of expectations, prompting a sharp valuation reset even as quarterly revenue and earnings topped forecasts.
Chip Rebound Powers Wall Street Higher, but Nasdaq Breadth Remains Weak
Wall Street closed higher Tuesday, led by a 5.5% surge in chip stocks, though Nasdaq breadth remained weak with 103 new lows vs 41 new highs.
Semiconductor surge lifts US stocks, but market breadth remains mixed
US stocks rose Tuesday as the chip index jumped 4.9%, but market breadth remained uneven. The Nasdaq gained 1.29% and the S&P 500 added 0.81%.
Danaher Shares Plunge 14% on Reduced Growth Forecast and Bioprocessing Gap
Danaher (DHR) stock dropped 14% after the company slashed its 2026 core-revenue growth forecast to 3%-4%, citing a bioprocessing order-to-revenue gap that overshadowed a quarterly earnings beat.
Navigating Market Volatility: A Beginner's Guide to U.S. Equity Investing
U.S. equity futures declined Tuesday amid AI disruption fears and geopolitical focus. For novice investors, the backdrop features falling fund costs but rising market uncertainty.
Thermo Fisher Shares Extend Slide Amid Clario Acquisition Financing
Thermo Fisher Scientific shares declined 0.98% to $504.82 on Friday, extending a recent downturn. The company has raised $3.8 billion in senior notes to partially fund its acquisition of clinical data firm Clario.
Danaher Shares Extend Decline Ahead of Key Fed, Economic Data
Danaher shares dropped 1.1% Friday, continuing a two-session decline. Trading volume was active as markets prepare for a holiday closure and a data-heavy week ahead.
Thermo Fisher Prices $3.8B Bond Offering to Fund Clario Acquisition
Thermo Fisher Scientific raised $3.8 billion through a multi-tranche bond offering to fund its planned Clario acquisition. Shares closed down nearly 1% on Friday.
Danaher Shares Slip Ahead of Holiday, Traders Eye PCE Data
Danaher shares fell in extended trading Friday, closing near $212.58. The dip precedes a market holiday, with attention shifting to next week's key inflation report.
Thermo Fisher Files Multi-Tranche Bond Offering to Finance Clario Acquisition
Thermo Fisher Scientific shares edged higher Monday after filing a preliminary prospectus for a four-part senior notes offering to fund its planned Clario acquisition. The company reported consolidated debt of $39.38 billion as of December 31, 2025.
Thermo Fisher Shares End Week Lower Amid Research Funding Concerns
Thermo Fisher Scientific closed Friday at $542.83, down 6.7% for the week as investors weigh pressure from academic research funding cuts. The company's 2026 outlook projects adjusted earnings of $24.22 to $24.80 per share.
Thermo Fisher Shares Stabilize After 4% Drop as Plant Closure and Macro Data Loom
Thermo Fisher Scientific's stock held near $543 Friday following a sharp decline. The company plans to close a Massachusetts facility by 2026, affecting 80 jobs, while investors await key U.S. economic reports.